Abstract
Background Skeletal muscle mass and function are crucial for assessing physical frailty, sarcopenia, and cachexia, which significantly impact the prognosis of geriatric patients with heart failure (HF). Ultrasound-based assessment of skeletal muscles offers a non-invasive, real-time alternative to traditional methods. The compariSON of various methods In evaluatIon of sarCopenia in patients with Heart Failure study (SONIC-HF) aimed to evaluate the feasibility and prognostic impact of ultrasound-based muscle assessment in geriatric patients with HF.
Methods This multicenter, prospective cohort study enrolled HF patients aged ≥65 years who could ambulate independently at discharge. Certified observers assessed muscle thickness (biceps, quadriceps, rectus femoris, and diaphragm) using ultrasound at rest and during contraction. The primary endpoint was all-cause mortality. Secondary endpoints included HF hospitalization, unplanned hospital visits, and cardiovascular and non-cardiovascular mortality.
Results Of the 692 enrolled patients (median age 81 (IQR 74–86) years, 57.6% female, left ventricular ejection fraction 45% (32%–60%)), ultrasound-based muscle assessments were completed in 606 patients. Interobserver reliability was excellent (intraclass correlation coefficient 0.84–0.99). Median muscle thicknesses at rest and during contraction were: diaphragm 1.9 (1.6–2.3) mm and 2.9 (2.3–3.8) mm; biceps 19.6 (15.9–23.1) mm and 25.3 (21.3–29.5) mm; quadriceps 19.0 (15.0–23.5) mm and 24.8 (19.9–29.5) mm; rectus femoris 9.7 (7.1–12.3) mm and 12.1 (9.6–15.0) mm. The median follow-up time was 733.5 (438–882) days.
Conclusions The SONIC-HF registry will provide valuable insights into the feasibility and prognostic implications of ultrasound-based muscle assessment in geriatric patients with HF.
Competing Interest Statement
N. K. was affiliated with a department endowed by grants Paramount Bed, received research grants from EchoNous. Inc. and AMI Inc., and received an honorarium from Novartis Japan, Otsuka Pharma, Eli Lilly, and Nippon Boehringer Ingelheim outside the submitted work. Y. M. received an honorarium from Otsuka Pharmaceutical Co., Novartis Japan, AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Bayer Japan, and Pfizer, Inc., and research funding outside the submitted work from Nippon Boehringer Ingelheim Co., LTD., Pfizer Inc., Otsuka Pharmaceutical Co., EN Otsuka Pharmaceutical Co., Ltd., and Roche Diagnostics Japan.. K. K. received funding outside the submitted work from Eiken Chemical Co., Ltd. and SoftBank Cor. Ltd. The other authors have no conflicts of interest to declare.
Funding Statement
This study was partially supported by the NOVARTIS Foundation (Japan) for the Promotion of Health and by Japan Society for the Promotion of Science KAKENHI (grant number 19K11424).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Sakakibara Heart Institute of Okayama gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- BNP
- B-type natriuretic peptide
- MRI
- magnetic resonance imaging
- NYHA
- New York Heart Association
- HF
- heart failure
- HR
- hazard ratio
